Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment

B. J. Rimel, Aaron Ferda, Jamie Erwin, Summer B. Dewdney, Leigh Seamon, Feng Gao, Christopher Desimone, Kristen K. Cotney, Warner Huh, L. Stewart Massad

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Objective: To evaluate the utility of liquid-based cytology in detecting recurrent cervical cancer among treated cervical cancer patients. Methods: A retrospective multi-institution study identified patients treated for cervical cancer from January 1, 2000, to November 1, 2009, through local cancer registries and patient databases. Patients were excluded if they lacked follow-up or treatment data. Results: In all, 4,167 cytology results from 929 women were identified. Of these, 626 (15%) Pap test results from 312 (34%) women were abnormal, including 296 atypical squamous cells of undetermined significance (ASC-US; 47%); 179 low-grade squamous intraepithelial lesions (LSIL; 29%), 59 atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions (ASC-H; 9%); 55 high-grade squamous intraepithelial lesions (HSIL; 9%); 14 atypical glandular cells (2%), and 23 favor neoplasia (4%). Abnormal Pap test results led to 201 colposcopies in 135 women. Only 45 women had cervical intraepithelial neoplasia (CIN) 2 or worse, 25 had CIN 3, and 12 had cancer. Only 5 of 475 (1%) women with ASC-US or LSIL had CIN 3. Cancer recurred in 147 women, with 12 (8.1%) detected by Pap test; all but one had Pap test results of ASC-H or worse. One patient with ASC-US and human papillomavirus had a visible lesion on return for assessment 2 months after Pap testing. Colposcopy for cytology less than HSIL without a visible lesion on examination did not detect any recurrence or CIN 3. When stratified by stage and institution, patients treated with radiation had a higher risk of abnormal Pap test results (P<.001). Conclusion: A third of cervical cancer survivors will have abnormal cytology during follow-up, but in the absence of a visible lesion, those with ASC-US or LSIL can be followed without colposcopy unless abnormalities persist. Women with ASC-H, HSIL, and similar abnormalities deserve colposcopy.

Original languageEnglish
Pages (from-to)548-553
Number of pages6
JournalObstetrics and gynecology
Volume118
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint Dive into the research topics of 'Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment'. Together they form a unique fingerprint.

  • Cite this

    Rimel, B. J., Ferda, A., Erwin, J., Dewdney, S. B., Seamon, L., Gao, F., Desimone, C., Cotney, K. K., Huh, W., & Massad, L. S. (2011). Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment. Obstetrics and gynecology, 118(3), 548-553. https://doi.org/10.1097/AOG.0b013e3182271fdd